VSTM reports VS-7375 cancer-trial response results
The company reports 50% confirmed overall response rate in second-line pancreatic ductal adenocarcinoma and two complete responses in second-line-or-later disease.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.